CNBCLean R·
This medtech stock began trading less than a month ago. Goldman Sachs thinks it could double
The investment bank initiated coverage of the neurostimulation therapy developer with a buy rating.
Read at CNBC →
BBC
The investment bank initiated coverage of the neurostimulation therapy developer with a buy rating.
<iframe src="https://statesidedaily.com/embed/cluster/c26a729081a841f3aee4ec52df351aeca54f156e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="This medtech stock began trading less than a month ago. Goldman Sachs thinks it could double"></iframe>